Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it displays a valid OMR control number. Under the Paperwork Reduction Act of 1995

TRANSMIT	ΓAL
FORM	J.

(to be used for all correspondence after initial filing)-

09/782.587 Applicati n Number February 12, 2001 Filing Dat Anders Hjelholt Pedersen **First Named Inventor** Group Art Unit 1645 Unassigned **Examiner Name**

4 0212us310 Attorney Docket Number Total Number of Pages in This Submission **ENCLOSURES** (check all that apply) After Allowance Communication **Assignment Papers** Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Appeal Communication to Group Licensing-related Papers Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition After Final **Proprietary Information** Petition to Convert to a Affidavits/declaration(s) **Provisional Application** Status Letter Power of Attorney, Revocation Change of Correspondence Other Enclosure(s) (please **Extension of Time Request** Address identify below): **Terminal Disclaimer** Form PTO/SB/08A-B; **Express Abandonment Request** References 1-4: Request for Refund Return Postcard Suppl. Information Disclosure Statement CD, Number of CD(s). Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Authorization to charge deposit account: Incomplete Application Please charge deposit account no. 50-0990 for any additional Response to Missing Parts fees associated with this paper or during the pendency of this under 37 CFR 1.52 or 1.53 application. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Joanne R. Petithory, Reg. No. 42,995 COPY OF PAPERS Individual name ORIGINALLY FILED Signature Jùlv¹1, 2002 Date

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington DC 20231 on: July 1, 2002

Victoria A. MacMillan Typed or printed name a me mile July 1, 2002 Signature Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents, Washington, D.C. 20231

on July 1, 2002



RECEIVED

Jin. 1 2 2002

TECH CENTER 1600/2900

By Ciectrie A. MacMillan
Victoria A. MacMillan

Attorney Docket No. 0212us310

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Anders Hjelholt Pedersen, et al.

Application No.: 09/782,587

Filed: February 12, 2001

For: Factor VII or VIIa-like Molecules.

Examiner: Unassigned

Art Unit: 1774

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER

37 CFR § 1.97 and § 1.98

Assistant Commissioner for Patents Washington, D.C. 20231

COPY OF PAPERS ORIGINALLY FILED

Sir:

The references cited on attached form PTO-SB/08 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to a first Office action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the abovenoted Deposit Account.

Respectfully submitted,

Joanne R. Petithory Reg. No. 42,995

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, California 94063

Telephone: (650) 298-5300 Facsimile: (650) 298-5446

Customer No. 30560



Substitute for form 1449A-B/PTO

Examiner

Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

,	Application Number	omplet if Known
7	Application Number	09/782,587
	Filing Date	February 12, 2001
-	First Named Inventor	Anders Hjelh It Pedersen, et al.
1	Group Art Unit	1744
ı	Examiner Name	Unassigned
	Attorney Docket Number	0212us310

		U.S. Patent Do		J.S. PATENT DOCUMENTS Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,	
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal	
						CEIVED	
						RECLIVE	
						7111- 1 2 5005	
			1			TECH CENTER 1600	
						LECH CLIVIE	

	Foreign Patent Document		N PATENT DOCUMENT	Date of Publication	Pages, Columns, Lines,	T	
Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	1
			<u> </u>				
			-	•			L
		<u>.</u>	ļ				_
							_
							L
		Cite	Cite	Cite Kind Code	Cite Kind Code Name of Patentee or	Cite Kind Code Name of Patentee or of Cited Document	Cite Kind Code Name of Patentee or of Cited Document Where Relevant Passages

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No/	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	1/	CHEUNG, WING-FAI et al., "Localization Of An E0pitope Of A Calcium-Dependent Monoclonal Antibody To The N-Terminal Region Of The GLA Domain Of Human Factor VII", Thrombois Research, (1995), 79(2): 199-206	
	2	DICKINSON, CRAIG D. et al., "Influence of Cofactor Binding and Active Site Occupancy on the Conformation of the Macromolecular Substrate Exosite Of Factor VIIa", <i>J. Mol. Bio.</i> (1998) 277:959-971	
	3 /	JIN, JIANPING et al., "Four Loops of the Catalytic Domain of Factor VIIa Mediate the Effect of the First EGF-like Domain Substitution on Factor VIIa Catalytic Activity", J. Mol. Bio. (2001) 307:1503-1517	
	4	NEUENSCHWANDER, PIERRE F. et al., "Alteration of the Substrate and Inhibitor Specificities of Blood Coagulation Factor VIIa: Importance of Amino Acid Residue K192", Biochemistry, (1995) 34:8701-8707	

EXAMINER :	Initial if reference of	onsidered	I, whether or not citatio	n is in conformance	with MPEP 609.	Draw lin	through citation if not in
conformance	and not considered.	Includ (copy of this form with n	xt communication	to apolicant.		

COPY OF PAPERS ORIGINALLY FILED

Date

Considered